In the News: Ubiquinol Form of CoQ10 Improves Insulin Sensitivity in Prediabetic Adults

Ubiquinol Form of CoQ10 Improves Insulin Sensitivity in Prediabetic Adults

A randomized controlled pilot study that evaluated the effects of the ubiquinol form of coenzyme Q10 (CoQ10) in men and women with prediabetes showed a reduction in insulin resistance among those who were given CoQ10 compared with participants who received a placebo.*

The trial enrolled 20 prediabetic individuals between the ages of 18–60 years. Ten participants were given 100 mg of ubiquinol in medium-chain triglyceride oil, while the remainder received a placebo daily for 12 weeks.

Laboratory values, including assessment of insulin resistance, glucose, hemoglobin A1c and lipids, were measured at the beginning and end of the trial.

After 12 weeks, participants who received CoQ10 had significantly lower insulin resistance compared with the placebo group.

Editor's Note: "One hundred milligrams ubiquinol for 12 weeks improves insulin sensitivity for prediabetic patients with a favorable safety profile," the authors concluded.

^* Clin Nutr Open Sci. 2026 Apr;66:100627.

Vitamin D Shows Promise in Inflammatory Bowel Disease

Vitamin D may help regulate the overactive immune response to gut bacteria that occurs in inflammatory bowel disease (IBD), according to a recent study.*

Participants included 48 adults with IBD and low levels of vitamin D. They received a dose of 50,000 IU (1,250 mcg) of oral vitamin D once weekly for 12 weeks. Blood and stool samples were analyzed before and after treatment.

At the end of the study, participants showed higher vitamin D levels, reduced disease activity scores, and other positive outcomes. Improvements were also observed in gut microbiota composition and immune cell function, suggesting a potential role for vitamin D in restoring immune balance.

Editor's Note: Inflammatory bowel disease— including Crohn's disease and ulcerative colitis—is characterized by inflammation of the gastrointestinal tract. "Loss of immune tolerance to the gut microbiome plays a pathogenic role in inflammatory bowel disease (IBD)," the authors stated.

^* Cell Rep Med. 2026 Apr 21;7(4):102703.

Melatonin Lowers Cardiometabolic Risk Factors

Individuals who received melatonin demonstrated improvements in several risk factors for metabolic syndrome and cardiovascular disease, according to a systematic review and meta-analysis of clinical trials.*

The meta-analysis included 63 randomized controlled trials involving a total of 3,157 participants. Of these, 1,606 were given melatonin supplementation, while 1,551 were part of control groups.

Participants included healthy individuals or those with specific conditions such as metabolic syndrome.

Overall, melatonin supplementation was associated with significantly reduced hip circumference, systolic blood pressure, fasting blood glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, ALT (a liver enzyme), malondialdehyde (a marker of oxidative stress), and markers of inflammation that included C-reactive protein, tumor necrosis factor-alpha, and interleukin-6.

Editor's Note: Melatonin was additionally associated with improvement in serum total antioxidant capacity and an increase in high-density lipoprotein (HDL) cholesterol.

^* Nutrients. 2025 Dec 31;18(1):134.

Magnesium Associated with Lower 28-Day Mortality Rate in Heart Failure Patients

Heart failure patients with preserved ejection fraction (also known as diastolic heart failure), treated in an intensive care unit had a significantly lower 28-day risk of all-cause mortality when given magnesium compared to those who did not receive it.*

Researchers compared 985 patients who received magnesium with another 985 who did not. Within 28 days, 20% of the group not receiving magnesium died, whereas only 13.6% of the magnesium group died.

After adjustment for various confounding factors, magnesium intake was linked to a 32% lower risk of mortality.

Editor's Note: Subgroup analysis showed even greater benefits, with lower risk for certain groups: older patients: 35%, women: 45%, individuals without diabetes: 46% and patients with high blood pressure: 38%.

^* Sci Rep. 2025 Jan 14;15(1):1944.